PDCD1 and melanoma: So far, the anti-PD-1 antibodies have been FDA approved for the treatment of advanced melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin's lymphoma, urothelial cancer, gastric cancer and head and neck cancer (Figure 2).